Professor Subrata Ghosh – ITM Director
Office 4, Ground Floor
+44(0)121 371 8047
MD, FRCP, FRCPE, FRCPC, AGAF, FCAHS
Subrata Ghosh is the inaugural Director of the Institute of Translational Medicine, Birmingham, and Professor of Translational Medicine, University of Birmingham since June 2016. He sits on the College Board of the College of Medical and Dental Sciences, University of Birmingham. He is the gastroenterology theme lead of the inaugural NIHR Biomedical Research Centre, Birmingham.
Prior to this Professor Ghosh was the Professor and Chairman of Medicine at the University of Calgary, Canada and Head of Medicine, Alberta Health Services, Calgary. He served on the Dean’s Executive Council of the University of Calgary Medical Faculty. Between 2002 and 2008 he was the Professor and Chair of Gastroenterology at Imperial College London, Hammersmith Hospital. Prior to this, he was consultant gastroenterologist and honorary senior lecturer at the University of Edinburgh. He remains adjunct professor of medicine at the University of Calgary (Canada).
Professor Ghosh is a Fellow of the Canadian Academy of Health Sciences and theme lead for integration cluster of the International Organisation for Study of IBD (IOIBD). He has published over 440 manuscripts in international journals including the New England Journal of Medicine, Lancet, Nature Medicine, Gastroenterology and Gut, and delivered over 700 international lectures including named lectures. His research interests are precision medicine in IBD, immune cell plasticity, targeted therapies in IBD, epidemiology of IBD, interaction of nutrients and immune system and standards of care. He has been the recipient of multiple individual and large team grants from CIHR, AIHS, MRC, NIHR, Wellcome Trust, CCUK and CCC, as well as numerous industry partnered research projects. He has served on numerous committees, councils and grant panels regionally, nationally and internationally, and been chief editor, associate editor and editorial board member of a number of reputable international journals.
He is very well connected internationally, both through personal research as well as strategic organisational links with institutions in North America, China, Australia and Japan (including the University of Calgary, Chinese University of Hong Kong, Rouen University INSERM Unit, University of Ehrlangen-Nurnberg, GSK, Abbvie and Janssen).
Future plans: to develop new targeted therapies in IBD, epidemiology of IBD, standard of care and patient reported outcomes in IBD.
Keywords: Biological therapies in IBD, Immune cell plasticity, Inflammatory bowel disease, gastroenterology